Raremark, a London, UK-based rare disease patient-data platform, raised £3m in funding.
The round was led by AlbionVC and Ananda Ventures, with participation from Oltre Venture and existing major investor the Cass Entrepreneurship Fund.
The company intends to use the funds to develop its patient-engagement and data-analysis technology, which allows biopharmaceutical companies to identify, engage and learn from patients, accelerating the development of new treatments.
Led by Julie Walters, CEO and founder, Raremark provides a machine-learning tech platform for building research networks of rare disease patients and their families. The company provides biopharmaceutical companies with access to anonymized and aggregated patient data, to reduce the time and cost of clinical development, to raise health literacy and informed participation in medical research, to improve the quality of existing therapies and to find new ones.
The company also has an office in Boston, US.
FinSMEs
22/10/2018